Ornidazole-Induced Liver Injury: The Clinical Characterization of a Rare Adverse Reaction and Its Implications from a Multicenter Study
Authors:
- Ali Rıza ÇalışkanAÇAli Rıza Çalışkan
- Ilker TuranITIlker Turan
- Sezgin VatanseverSVSezgin Vatansever
- Jasmin WeningerJWJasmin Weninger
- Emine Türkmen ŞamdancıEŞEmine Türkmen Şamdancı
- Ayşe Nur AkatliAAAyşe Nur Akatli
- Elvan IşıkEIElvan Işık
- Esra DurmazerEDEsra Durmazer
- Ayşenur ArslanAAAyşenur Arslan
- Nilay DanışNDNilay Danış
- Hüseyin KaçmazHKHüseyin Kaçmaz
- Sedat CicekSCSedat Cicek
Open Access
- 11 July 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (7) , 1695
Abstract
Background and Aims: Ornidazole, a nitroimidazole antibiotic, is widely used for protozoal and anaerobic infections and is generally considered safe. However, ornidazole-induced liver injury (OILI) is an underrecognized yet potentially severe adverse reaction. This multicenter study aims to characterize the clinical features, histopathology, and outcomes of OILI to improve the awareness and management of this rare entity worldwide. Methods: We conducted a retrospective analysis of 101 patients with OILI from eight tertiary centers between 2006 and 2023. Cases were included based on liver enzyme elevations temporally linked to ornidazole and the exclusion of other causes. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) score. Clinical data, laboratory parameters, autoantibody profiles, histology, treatments, and outcomes were evaluated. Results: OILI was classified as highly probable in 42.6% of cases (n = 43), probable in 51.5% of cases (n = 52), and possible in 5.9% (n = 6) of cases. The predominant pattern was acute hepatocellular injury (83.2%) (n = 84). Autoimmune-like hepatitis occurred in 5% of cases (n = 5), with ANA positivity in 16.8% of cases (n = 17). Corticosteroids were used in 24.8% of cases (n = 25) and were associated with higher ANA positivity and a 20% (n = 5) relapse rate post-discontinuation. Recovery was achieved in 87.7% of cases (n = 88), while 7.9% of cases (n = 8) required liver transplantation and 4% (n = 4) died. Conclusions: Ornidazole can cause serious idiosyncratic liver injury, including autoimmune phenotypes, and should be considered in the differential diagnosis of acute hepatitis. Given the notable risk of liver failure and death, early recognition, drug discontinuation, and close monitoring are essential. In select cases, corticosteroids and plasmapheresis may be beneficial, though the evidence remains limited.Keywords
This publication has 36 references indexed in Scilit:
- Arzneimittelinduzierte immunvermittelte LeberschädigungDie Innere Medizin, 2024
- AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injuryHepatology, 2023
- Drug-Induced Liver InjuryCritical Care Nursing Clinics of North America, 2022
- Clinical management of patients with drug‐induced liver injury (DILI)United European Gastroenterology Journal, 2021
- Drug induced liver injury: an updateArchives of Toxicology, 2020
- Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of SteroidsClinical Gastroenterology and Hepatology, 2017
- Features of Autoimmune Hepatitis in Patients With Drug-induced Liver InjuryClinical Gastroenterology and Hepatology, 2017
- Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort studyDigestive and Liver Disease, 2014
- Steroid Use in Acute Liver FailureHepatology, 2013
- Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallengeJournal of Clinical Epidemiology, 1993